Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 19/20 | 0.55 |
| ▸ | HTR1B | P28222 | 19/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28725598 | 0.92 | HTR1D (0.56) | HTR1DHTR1BKMT2A | |
| SCHEMBL28725580 | 0.89 | HTR1D (0.52) | HTR1DHTR1BMEN1LMNAMAPT | |
| SCHEMBL25223587 | 0.88 | HTR1D (0.51) | HTR1DHTR1BMEN1LMNAMAPT | |
| SCHEMBL28725616 | 0.88 | HTR1D (0.59) | HTR1DHTR1B | |
| SCHEMBL28435263 | 0.86 | MAPT (0.50) | HTR1DHTR1BMEN1LMNAMAPT | |
| SCHEMBL29555827 | 0.85 | GABRP (0.51) | HTR1DHTR1B | |
| SCHEMBL19761221 | 0.85 | GABRP (0.51) | HTR1DHTR1B | |
| SCHEMBL20557557 | 0.83 | MEN1 (0.47) | HTR1DHTR1BMEN1LMNAMAPT | |
| SCHEMBL29555690 | 0.83 | MEN1 (0.47) | HTR1DHTR1BMEN1LMNAMAPT | |
| SCHEMBL28725841 | 0.80 | HTR1D (0.38) | HTR1DHTR1BMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111448190-B | Substituted indole compounds | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-109923108-B | Pyridyl-substituted indole compounds | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-109715617-B | Dimethoxyphenyl-substituted indole compounds as inhibitors of TLR7, TLR8 or TLR9 | 百时美施贵宝公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-111448190-A | Substituted indole compounds | 百时美施贵宝公司 | 2020-07-24 | — | — | CN | disclosed |
| US-10660877-B2 | Pyridyl substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660877-B2 | Pyridyl substituted indole compounds | TLR7, TLR9, TLR1 | HTR1D 745/4885HTR1B 550/4885MEN1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.